Literature DB >> 12410217

Direct costs associated with a nosocomial outbreak of adenoviral conjunctivitis infection in a long-term care institution.

Emmanuel Piednoir1, Florence Bureau-Chalot, Corinne Merle, Athanaze Gotzamanis, Jocelyne Wuibout, Odile Bajolet.   

Abstract

BACKGROUND: In October 2000, 41 people were infected during an outbreak of adenoviral keratoconjunctivitis. Such nosocomial outbreaks are frequently reported in long-term care institutions, even though simple measures to prevent or limit such occurrences are well documented. This study describes the significant direct costs incurred as a result of this nosocomial outbreak that involved patients and staff.
METHODS: The costs measured in this study were grouped into the following 4 categories: medical, investigative, preventive, and lost productivity. Information about costs incurred by the hospital was gathered from a number of sources.
RESULTS: The outbreak cost the hospital US $29,527 ($1085 for medical costs, $8210 for investigative costs, $3048 for preventive measures, and $17,184 for lost productivity).
CONCLUSION: This study demonstrates the substantial expense incurred by 1 hospital as a result of an outbreak of a preventable disease. The measures necessary to prevent such a costly outbreak are simple and, therefore, cost-effective.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12410217     DOI: 10.1067/mic.2002.125193

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  9 in total

1.  An outbreak of epidemic keratoconjunctivitis in a regional ophthalmology clinic in New South Wales.

Authors:  K A Viney; P J Kehoe; B Doyle; V Sheppeard; A R Roberts-Witteveen; H Semirli; K A McPhie; D E Dwyer; J M McAnulty
Journal:  Epidemiol Infect       Date:  2007-11-30       Impact factor: 2.451

2.  2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings.

Authors:  Jane D Siegel; Emily Rhinehart; Marguerite Jackson; Linda Chiarello
Journal:  Am J Infect Control       Date:  2007-12       Impact factor: 2.918

Review 3.  Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis.

Authors:  Su-Hsun Liu; Barbara S Hawkins; Sueko M Ng; Mark Ren; Louis Leslie; Genie Han; Irene C Kuo
Journal:  Cochrane Database Syst Rev       Date:  2022-03-03

4.  Efficacy of topical immunoglobulins against experimental adenoviral ocular infection.

Authors:  Edward C Nwanegbo; Eric G Romanowski; Y Jerold Gordon; Andrea Gambotto
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-09       Impact factor: 4.799

5.  Ganciclovir ophthalmic gel treatment shortens the recovery time and prevents complications in the adenoviral eye infection.

Authors:  Serkan Ozen; Murat A Ozer
Journal:  Int Ophthalmol       Date:  2016-05-24       Impact factor: 2.031

6.  Human adenovirus type 8 epidemic keratoconjunctivitis with large corneal epithelial full-layer detachment: an endemic outbreak with uncommon manifestations.

Authors:  Yueh-Chang Lee; Nancy Chen; I-Tsong Huang; Hui-Hua Yang; Chin-Te Huang; Li-Kuang Chen; Min-Muh Sheu
Journal:  Clin Ophthalmol       Date:  2015-05-27

Review 7.  Closure of medical departments during nosocomial outbreaks: data from a systematic analysis of the literature.

Authors:  S Hansen; S Stamm-Balderjahn; I Zuschneid; M Behnke; H Rüden; R-P Vonberg; P Gastmeier
Journal:  J Hosp Infect       Date:  2007-03-12       Impact factor: 3.926

8.  Nosocomial outbreak of norovirus gastroenteritis and investigation of ABO histo-blood group type in infected staff and patients.

Authors:  E Meyer; W Ebner; R Scholz; M Dettenkofer; F D Daschner
Journal:  J Hosp Infect       Date:  2004-01       Impact factor: 3.926

9.  Detection of a broad range of human adenoviruses in respiratory tract samples using a sensitive multiplex real-time PCR assay.

Authors:  Sallene Wong; Kanti Pabbaraju; Xiaoli L Pang; Bonita E Lee; Julie D Fox
Journal:  J Med Virol       Date:  2008-05       Impact factor: 2.327

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.